Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ZL-1109 in Chinese adults with thyroid eye disease
CTR20253936Phase 3Active
- Sponsor
- Zai Lab
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of elegrobart in Graves Orbitopathy (GO), sponsored by Zai Lab. Started Dec 2025; status: active.
02
Drugs
elegrobart
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20253936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253936.